The National Medical Products Administration (NMPA) has approved marketing for two innovative medical devices: RocketHeart’s implantable left ventricular assist system and Our United Group’s gamma beam stereotactic radiation therapy system. Both products feature proprietary technologies and mark firsts in China’s medical device landscape.
RocketHeart’s LV Assist System
RocketHeart’s device provides mechanical circulatory support for patients with advanced refractory left heart failure, offering transitional treatment before heart transplantation or cardiac function restoration. The system integrates magnetic fluid suspension technology, making it China’s first implantable magnetic fluid suspension left ventricular assist device.
Our United Group’s Radiation Therapy System
Our United Group’s gamma beam system is designed for image-guided stereotactic radiation therapy, including head and body treatments for solid tumors. The device combines KV-level CBCT image guidance and real-time orthogonal imaging, positioning it as China’s first image-guided gamma ray stereotactic radiotherapy equipment. It optimizes daily quality control workflows to ensure irradiation dose accuracy.-Fineline Info & Tech
